There are 398 resources available
Immune biomarkers in mTNBC: Current and emerging
Presenter: Roberto Salgado
Session: Challenges and landscape of emerging approaches in metastatic triple negative breast cancer (mTNBC)
Resources:
Slides
Webcast
Health education and healthy lifestyles in breast cancer patients
Presenter: Julio de la Torre-Montero
Session: EONS - Supportive care issues in breast cancer
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Tailoring treatment for early HER2 breast cancer
Resources:
Webcast
Q&A
Presenter: All Speakers
Session: Antibody drug conjugates (ADCs) to treat breast cancer
Resources:
Webcast
New therapies on the horizon for mTNBC
Presenter: Sibylle Loibl
Session: Challenges and landscape of emerging approaches in metastatic triple negative breast cancer (mTNBC)
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: EONS - Supportive care issues in breast cancer
Resources:
Webcast
Q&A
Presenter: All Speakers
Session: Challenges and landscape of emerging approaches in metastatic triple negative breast cancer (mTNBC)
Resources:
Webcast
161O - VIOLETTE: Randomised Phase 2 Study of Olaparib (ola) + Ceralasertib (cer) or Adavosertib (ada) vs Ola Alone in Patients (pts) With Metastatic Triple-Negative Breast Cancer (mTNBC)
Presenter: Andrew Tutt
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 161O
Presenter: Valentina Guarneri
Session: Proffered Paper session 2
Resources:
Slides
Webcast
58O - Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
Presenter: Frederik Marmé
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast